AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20670466 — intervention group
Group type: COMPARATOR
Intervention: Control diet (35% of energy as fat)
Number of subjects: 106
Study 20670466 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 106
Study 17695946 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 207
Study 17695946 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 207
Study 15805229 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 15805229 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion (euglycemic insulin clamp; high insulin, suppressed FFA)
Number of subjects: 8
Study 15805229 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-heparin infusion (suppressed insulin, high FFA)
Number of subjects: 8
Study 10792200 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg cilansetron
Number of subjects: 12
Study 10792200 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg cilansetron
Number of subjects: 12
Study 10792200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9310023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms b.i.d. via diskhaler)
Number of subjects: 16
Study 9310023 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 16
Study 7506172 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 1.5 mg/kg/day 3 times daily
Number of subjects: 40
Study 7506172 — intervention group
Group type: COMPARATOR
Intervention: paracetamol 120 to 288mg (5 to 12ml) 3 times daily for 3 to 7 days
Number of subjects: 40
Study 2882289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (MMU‐18006) - 10^4 plaque-forming units, orally administered
Number of subjects: 247
Study 2882289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 31268481 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus fluorouracil-leucovorin (arm A)
Number of subjects: 229
Study 31268481 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab (arm B)
Number of subjects: 229
Study 28078540 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 2500 mg/m2/day for 12 months (16 cycles)
Number of subjects: 1304
Study 28078540 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 2500 mg/m2/day for 6 months (8 cycles)
Number of subjects: 1304
Study 25143556 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (PCT) 1 μg/day for 6 months
Number of subjects: 15
Study 25143556 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Paricalcitol (PCT) after 6 months
Number of subjects: 15
Study 23223106 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport group
Number of subjects: 52
Study 23223106 — intervention group
Group type: COMPARATOR
Intervention: Stationary group
Number of subjects: 52
Study 21660675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for calming Gan and suppressing hyperactive yang (CGSHY)
Number of subjects: 64
Study 21660675 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 64
Study 19186717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese herbal decoction (Culuanpao decoction, Cupailuan decoction, Cuhuangti decoction)
Number of subjects: 50
Study 19186717 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Clomiphene and intramuscular injection of Chorionic Gonadotropin
Number of subjects: 50
Study 19186717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication
Number of subjects: 50
Study 17107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 17107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 17107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 17107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 17107268 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label, uncontrolled trials
Number of subjects: 0
Study 14751651 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 76
Study 14751651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 76
Study 11216934 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker condom
Number of subjects: 283
Study 11216934 — intervention group
Group type: COMPARATOR
Intervention: Standard condom
Number of subjects: 283
Study 8344096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 1052
Study 8344096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 1052
Study 8344096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment (combined data)
Number of subjects: 1052
Study 8344096 — intervention group
Group type: COMPARATOR
Intervention: N/A (indicators of slow-healing)
Number of subjects: 1052
Study 8344096 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (in DU patients)
Number of subjects: 1052
Study 3575022 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of suspected foods, open challenges, and double‐blind food challenges
Number of subjects: 480
Study 3575022 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction of foods into the diet at 1- to 3-month intervals
Number of subjects: 480
Study 3575022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge at regular intervals
Number of subjects: 480
Study 30077298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 91
Study 30077298 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training for fentanyl ITS
Number of subjects: 91
Study 30077298 — intervention group
Group type: COMPARATOR
Intervention: Placebo fentanyl ITS
Number of subjects: 91
Study 26926639 — intervention group
Group type: EXPERIMENTAL
Intervention: LJP538
Number of subjects: 0
Study 26926639 — intervention group
Group type: EXPERIMENTAL
Intervention: LJP539
Number of subjects: 0
Study 26926639 — intervention group
Group type: EXPERIMENTAL
Intervention: CSJ148 (combination of LJP538 and LJP539)
Number of subjects: 0
Study 26926639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25450470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal dispersion 650 mg/5.2 mL (test 1)
Number of subjects: 38
Study 25450470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal dispersion 675 mg/5.4 mL (test 2)
Number of subjects: 38
Study 25450470 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation 800 mg/20 mL (reference)
Number of subjects: 38
Study 23339978 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m2 administered intravenously on day 1 of a 3-week cycle.
Number of subjects: 50
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C-rich fruit and vegetable intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 2533
Study 21955649 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene-rich fruit and vegetable intake
Number of subjects: 2533
Study 18279523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamin (2400 mg/d)
Number of subjects: 70
Study 18279523 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg/d)
Number of subjects: 70
Study 18279523 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (Glucosamine sulfate 1500 mg/d + Aquamin 2400 mg/d)
Number of subjects: 70
Study 18279523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16536135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated participants with lower WRAT3 scores
Number of subjects: 120
Study 16536135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 120
Study 16536135 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with lower cognitive reserve (WRAT3 scores)
Number of subjects: 120
Study 16536135 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' perception of high- and low-risk partners
Number of subjects: 120
Study 14518597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg
Number of subjects: 372
Study 14518597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 372
Study 14518597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 10863250 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity program based on operant therapy
Number of subjects: 0
Study 10863250 — intervention group
Group type: COMPARATOR
Intervention: Usual care in physiotherapy (pain-contingent)
Number of subjects: 0
Study 10863250 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity program
Number of subjects: 0
Study 10863250 — intervention group
Group type: COMPARATOR
Intervention: Usual care in physiotherapy
Number of subjects: 0
Study 7974348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 18
Study 7974348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 18
Study 7974348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2493869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium restriction for three months (n = 17)
Number of subjects: 34
Study 2493869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (Slow Sodium 80 mmol daily) for one month
Number of subjects: 34
Study 2493869 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 34
Study 2493869 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetic diet (control group)
Number of subjects: 34
Study 30668274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal rTPJ HD-tDCS
Number of subjects: 0
Study 30668274 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 28526798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 28526798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26468853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar levobupivacaine hydrochloride and dexamethasone infiltration
Number of subjects: 40
Study 26468853 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar saline infiltration (Control Group)
Number of subjects: 40
Study 26468853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 23328319 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-frequency TENS (4 Hz for 3 s/110 Hz for 3 s) at low intensity (strong but comfortable)
Number of subjects: 208
Study 23328319 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-frequency TENS (4 Hz for 3 s/110 Hz for 3 s) at high intensity (strong and uncomfortable but not painful)
Number of subjects: 208
Study 23328319 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 208
Study 23328319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 208
Study 21308825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with an extract from Phaseolus vulgaris and Cynara scolymus for 2 months
Number of subjects: 39
Study 21308825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19122550 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (bolus injection of 0.031 mg.kg(‐1) and continuous infusion at a rate of 0.01 mg.kg(‐1).min(‐1))
Number of subjects: 25
Study 19122550 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control Group B)
Number of subjects: 25
Study 19122550 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (Group A)
Number of subjects: 25
Study 17322413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg)
Number of subjects: 20
Study 17322413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15447905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt (DFS) with 25 microg I/g salt and 2 mg Fe/g salt
Number of subjects: 158
Study 15447905 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 158
Study 11464036 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporesection (TUVRP)
Number of subjects: 185
Study 11464036 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection (TURP)
Number of subjects: 185
Study 9541184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nottingham Prognostic Index with ER and PgR
Number of subjects: 1629
Study 9541184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nottingham Prognostic Index without ER and PgR
Number of subjects: 1629
Study 9541184 — intervention group
Group type: COMPARATOR
Intervention: Danish index
Number of subjects: 1629
Study 9541184 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk patients with positive hormone receptors
Number of subjects: 1629
Study 8772223 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic pentasaccharide (SR 90107/ORG 31540) administered subcutaneously at doses of 4000, 8000, or 12,000 anti-Xa units (6, 12, or 18 mg)
Number of subjects: 0
Study 8772223 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic pentasaccharide (SR 90107/ORG 31540) at 12,000 anti-Xa units
Number of subjects: 0
Study 8772223 — intervention group
Group type: COMPARATOR
Intervention: Fraxiparine at 13,000 IU
Number of subjects: 0
Study 1699443 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-HES solution (72 g/l NaCl, 60 g/l HES, 2400 mosmol/l)
Number of subjects: 90
Study 1699443 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES solution (200/0.5)
Number of subjects: 90
Study 1699443 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-HES
Number of subjects: 90
Study 1699443 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES
Number of subjects: 90
Study 1699443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 1699443 — intervention group
Group type: EXPERIMENTAL
Intervention: HES
Number of subjects: 90
Study 6110218 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutroline (CP-36,584)
Number of subjects: 0
Study 31311521 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker deployment
Number of subjects: 380000
Study 28685497 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sample method
Number of subjects: 0
Study 28685497 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in posttests
Number of subjects: 0
Study 25330866 — intervention group
Group type: EXPERIMENTAL
Intervention: Men-only group workshops
Number of subjects: 283
Study 25330866 — intervention group
Group type: COMPARATOR
Intervention: Health partner group workshops
Number of subjects: 283
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV (3.5 mg/kg)
Number of subjects: 90
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV (7.1 mg/kg)
Number of subjects: 90
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV (14.2 mg/kg)
Number of subjects: 90
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV administered 12 h postexposure
Number of subjects: 90
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV administered 24 h postexposure
Number of subjects: 90
Study 23979731 — intervention group
Group type: EXPERIMENTAL
Intervention: AIGIV in trigger-based intervention studies
Number of subjects: 90
Study 21829969 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid (ACG)
Number of subjects: 104
Study 21829969 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin plus ceftriaxone (OCG)
Number of subjects: 104
Study 19481656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeway method (ILTR)
Number of subjects: 34
Study 19481656 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (C group)
Number of subjects: 34
Study 17284637 — intervention group
Group type: COMPARATOR
Intervention: EP01572 (0.005, 0.05, 0.5 mg/kg body weight)
Number of subjects: 36
Study 17284637 — intervention group
Group type: EXPERIMENTAL
Intervention: EP01572 (0.125 and 0.25 mg/kg body weight)
Number of subjects: 36
Study 17284637 — intervention group
Group type: EXPERIMENTAL
Intervention: ID administration of EP01572 (0.2 mg/kg body weight)
Number of subjects: 36
Study 17284637 — intervention group
Group type: EXPERIMENTAL
Intervention: ID perfusion of EP01572 (0.35 mg/kg body weight)
Number of subjects: 36
Study 17284637 — intervention group
Group type: EXPERIMENTAL
Intervention: ID perfusion of EP01572 (0.5 mg/kg body weight)
Number of subjects: 36
Study 17284637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36
Study 15123848 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of fluoxetine
Number of subjects: 101
Study 15123848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium or desipramine augmentation
Number of subjects: 101
Study 15123848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study 11310719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg twice daily
Number of subjects: 105
Study 11310719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 30, 45 and 60mg oral suspension recommended twice daily based on weight
Number of subjects: 105
Study 11310719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg capsule
Number of subjects: 105
Study 11310719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 9415368 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects instructed to hold fixation on the cross and ignore the disparity modulation of the noise pattern
Number of subjects: 0
Study 9415368 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects instructed to follow the movement of the noise pattern as accurately as possible
Number of subjects: 0
Study 8116721 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled pulsatile infusion
Number of subjects: 358
Study 8116721 — intervention group
Group type: COMPARATOR
Intervention: Aggressively managed continuous infusion
Number of subjects: 358
Study 8116721 — intervention group
Group type: COMPARATOR
Intervention: Conservatively managed continuous infusion
Number of subjects: 358
Study 3054197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mcg/kg of Bpr combined with local anesthetic (group B)
Number of subjects: 30
Study 3054197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mcg/kg of Bpr combined with local anesthetic (group C)
Number of subjects: 30
Study 3054197 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only (group A)
Number of subjects: 30
Study 30459099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/every 2 weeks) plus Probiotic (8 × 10^9 CFU/day)
Number of subjects: 87
Study 30459099 — intervention group
Group type: COMPARATOR
Intervention: Probiotic (8 × 10^9 CFU/day)
Number of subjects: 87
Study 28796075 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle gap approach under a minimally invasive channel technique
Number of subjects: 68
Study 28796075 — intervention group
Group type: COMPARATOR
Intervention: Median approach
Number of subjects: 68
Study 26599332 — intervention group
Group type: EXPERIMENTAL
Intervention: HspB5 (7.5, 12.5, or 17.5 mg)
Number of subjects: 0
Study 26599332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24077070 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based anger-management intervention
Number of subjects: 27
Study 24077070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity ratings
Number of subjects: 27
Study 21182345 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r 600 mg/100 mg twice a day)
Number of subjects: 0
Study 21182345 — intervention group
Group type: COMPARATOR
Intervention: Control protease inhibitor (PI)-based HAART
Number of subjects: 0
Study 18245961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound phacoemulsification (group 1)
Number of subjects: 42
Study 18245961 — intervention group
Group type: COMPARATOR
Intervention: Fluid-based system (group 2)
Number of subjects: 42
Study 16389204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone maintenance
Number of subjects: 319
Study 16389204 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 319
Study 12535809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (50 mg/h)
Number of subjects: 84
Study 12535809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (100 mg/h)
Number of subjects: 84
Study 12535809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10781482 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling 66% N(2)O in O(2) (Group FN)
Number of subjects: 117
Study 10781482 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 66% N(2)O in O(2) (Group PN)
Number of subjects: 117
Study 10781482 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling 100% O(2) (Group FO)
Number of subjects: 117
Study 8923551 — intervention group
Group type: COMPARATOR
Intervention: Surround stationary
Number of subjects: 0
Study 8923551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround motion increased
Number of subjects: 0
Study 8923551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround motion same or opposite direction
Number of subjects: 0
Study 1395985 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-piece Conseal system (Group A)
Number of subjects: 57
Study 1395985 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece Conseal system (Group B)
Number of subjects: 57